Drug intelligence / Profile preview

cyclopentolate + phenylephrine

Development stage
Unknown
Lead developer
Alcon
Modality
Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Ophthalmic
01

Overview

Cyclopentolate + phenylephrine is a fixed-dose combination ophthalmic solution used to induce mydriasis (pupil dilation) for diagnostic eye examinations. Cyclopentolate is an anticholinergic agent that relaxes the sphincter muscle of the iris, leading to pupil dilation and some paralysis of accommodation (cycloplegia). Phenylephrine is an adrenergic agonist that stimulates alpha-1 adrenergic receptors in the dilator muscle of the iris, causing further pupil dilation through vasoconstriction. The combination provides greater mydriatic effect than either drug alone at their respective concentrations, with minimal cycloplegia. It is commonly used prior to eye exams or procedures requiring a dilated pupil[1][2][4][5].

Brand names
Cyclomydril
Other names
cyclopentolate and phenylephrine ophthalmiccyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution
02

Targets

CHRM4 (M4)CHRM3 (M3)ADRA1A (α1A)

Beyond the preview

Go deeper on cyclopentolate + phenylephrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclopentolate + phenylephrine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call